The 8th T-Cell Engager Therapeutics Summit

Biointron is pleased to announce our participation in the 8th T-Cell Engager Therapeutics Summit 2026, taking place June 23–25, 2026, in San Diego, California. 

The T-Cell Engager Therapeutics Summit is a leading industry forum dedicated to advancing the discovery, engineering, and clinical translation of T-cell engager (TCE) therapies. The 2026 meeting will bring together over 120 industry participants and 28+ expert speakers across biopharma and biotech to share insights on next-generation engager design, target selection, safety optimization, and strategies for improving efficacy in solid tumors and beyond.  

With a strong focus on end-to-end development, the summit features dedicated tracks spanning discovery and engineering through preclinical and clinical translation, as well as deep-dive workshops and extensive networking opportunities. The event reflects the growing momentum in immune-redirecting therapies, driven by increased investment, partnerships, and innovation across oncology and autoimmune indications.  

Biointron looks forward to connecting with partners and peers in San Diego and engaging in discussions that are shaping the next generation of T-cell engager therapeutics. 

For more details about the event, please visit the 8th T-Cell Engager Therapeutics Summit website [https://cell-engager-summit.com/] 

Time: June 23 - 25, 2026 

Location: Westin San Diego Bayview | San Diego, CA 

Booth: TBD